New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News For MDT;COV;INTC;BSX;VRTX;JNJ From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
<< 1 | 2 | 3 | 4 | all recent news | >>
November 21, 2014
06:05 EDTINTCIntel may not reach goal of shipping 70M tablet chips next year, Re/code reports
Intel CEO Bryan Krzanich said in an interview on the sidelines of the company's investor meeting that the company may not ship 70M tablet chips in 2015 as previously predicted, Re/code reports. Krzanich commented, "I donít think our standalone number will be that high." Reference Link
November 20, 2014
16:24 EDTINTCOn The Fly: Closing Wrap
Subscribe for More Information
13:59 EDTINTCIntel remains a top pick at Wells Fargo
Wells Fargo says Intel's outlook for 2015 is "roughly consistent" with its estimates. It expects Intel's competitive strength to profitability and share value over the next several years. The firm views Intel as a top pick and keeps an Outperform rating on the stock.
12:34 EDTINTCIntel sees FY15 R&D spending approximately $20B, plus or minus $400M
Subscribe for More Information
12:33 EDTINTCIntel sees FY15 CapEx approximately $10.5B, plus or minus $500M
Subscribe for More Information
12:32 EDTINTCIntel sees FY15 gross margin 62%, plus or minus two points
12:32 EDTINTCIntel sees FY15 revenue growth in mid-single digits, consensus $57.78B
12:31 EDTINTCIntel raises annual dividend to 96c per share
Subscribe for More Information
11:52 EDTINTCIntel CEO confirms organizational change made this week
The Wall Street Journal reported earlier this week that Intel has reorganized by combing its groups that handle personal computer chips with those used for smartphones and tablets, and Intel CEO Brian Krzanich confirmed the change during the company's investor day presentation.
11:32 EDTINTCIntel says high-end gaming segment among fastest growing in PCs
Subscribe for More Information
07:31 EDTBSXBoston Scientific should be bought on weakness, says RBC Capital
Subscribe for More Information
05:14 EDTCOVCovidien achieves CE Mark for Nellcor Bedside SpO2 Patient Monitoring System
Subscribe for More Information
November 19, 2014
13:42 EDTVRTXVertex peak CF sales have bullish read from Royalty Pharma bet, TheStreet says
Subscribe for More Information
12:11 EDTBSXBoston Scientific says Synergy stent met primary endpoint in trial
In the first successful U.S. pivotal trial of a bioabsorbable polymer stent, the Boston Scientific SYNERGY Everolimus-Eluting Bioabsorbable Polymer Platinum Chromium Coronary Stent System met its primary endpoint in this non-inferiority study, which evaluated the one-year rate of target lesion failure. Additionally, favorable rates for key secondary endpoints were observed with the SYNERGY Stent. Dean Kereiakes, M.D., F.A.C.C., F.S.C.A.I., the principal investigator for the EVOLVE II Trial, presented the study results today in a Late Breaking Clinical Trial session at the American Heart Association Scientific Session 2014 in Chicago. Key findings for the SYNERGY Stent from the EVOLVE II Trial include the following: At 12 months, the TLF rate was 6.4% per protocol and 6.7% for intent-to-treat. Stent Thrombosis was rare, with Definite or Probable ST occurring in only 0.4% of patients through one year. No Definite ST occurred after 24 hours.
10:42 EDTVRTXUBS hosts a conference call with Vertex Pharmaceuticals
Subscribe for More Information
10:29 EDTINTCGoogle now top competitor to Apple, Jefferies says
Subscribe for More Information
09:04 EDTJNJJohnson & Johnson submits NDA for three-month paliperidone palmitate
Janssen Research & Development, a Johnson & Johnson company, announced the submission of a New Drug Application, or NDA, for three-month atypical antipsychotic paliperidone palmitate to the FDA. The NDA seeks approval for the medication as a treatment for schizophrenia in adults. If approved, it will be the first and only long-acting atypical antipsychotic that has a four times a year dosing schedule.
08:15 EDTCOV, MDTMedtronic reported solid Q2 results, says Bernstein
Bernstein notes that Medtronic's (MDT) sales growth accelerated to 5%, and the firm thinks the company's market share of the ICD market is poised to increase next quarter. Bernstein views Medtronic as "a strong buy" into the close of its acquisition of Covidien (COV). The firm reiterates an Outperform rating on Medtronic.
07:52 EDTVRTXInforma Business Information to hold a conference
Subscribe for More Information
07:27 EDTVRTXRoyalty Pharma acquires royalties on Vertex Pharmaceuticals CF treatments
Subscribe for More Information
<< 1 | 2 | 3 | 4 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use